Last updated: February 19, 2026
What is the core invention of patent PL2558448?
Patent PL2558448, granted on November 29, 2021, to Sandoz AG, protects a stable crystalline form of valsartan. Valsartan is an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure. The patent specifically claims a crystalline form of valsartan characterized by certain X-ray powder diffraction (XRPD) data, differential scanning calorimetry (DSC) data, and infrared spectroscopy (IR) data [1]. This specific crystalline form, referred to as Form I, is presented as being more stable than other known forms of valsartan, particularly Form II [2].
What are the key claims of the patent?
The patent includes several claims defining the scope of protection. Claim 1 is the broadest, defining the crystalline form of valsartan.
- Claim 1: A crystalline form of valsartan, characterized by an XRPD pattern comprising peaks at approximately the following 2-theta angles: 7.2 ± 0.2°, 12.4 ± 0.2°, 14.3 ± 0.2°, 15.7 ± 0.2°, 20.5 ± 0.2°, 21.8 ± 0.2°, 22.3 ± 0.2°, 23.6 ± 0.2°, 24.6 ± 0.2°, 26.2 ± 0.2°, 27.6 ± 0.2° and 30.7 ± 0.2° [1].
- Claim 2: A crystalline form of valsartan according to claim 1, characterized by DSC data showing an endotherm with a peak maximum at approximately 120 ± 2°C [1].
- Claim 3: A crystalline form of valsartan according to claim 1 or 2, characterized by IR spectroscopy data comprising characteristic absorption bands at approximately the following wave numbers: 3427 ± 5 cm⁻¹, 3375 ± 5 cm⁻¹, 3287 ± 5 cm⁻¹, 1678 ± 5 cm⁻¹, 1638 ± 5 cm⁻¹, 1597 ± 5 cm⁻¹, 1470 ± 5 cm⁻¹, 1390 ± 5 cm⁻¹, 1291 ± 5 cm⁻¹, 1259 ± 5 cm⁻¹, 1158 ± 5 cm⁻¹, 1068 ± 5 cm⁻¹, 973 ± 5 cm⁻¹, 932 ± 5 cm⁻¹, 866 ± 5 cm⁻¹, 808 ± 5 cm⁻¹, 767 ± 5 cm⁻¹, 731 ± 5 cm⁻¹, 693 ± 5 cm⁻¹, 647 ± 5 cm⁻¹, 612 ± 5 cm⁻¹ and 547 ± 5 cm⁻¹ [1].
- Claim 4: A process for obtaining the crystalline form of valsartan according to claim 1, comprising crystallizing valsartan from an organic solvent or a mixture of organic solvents [1].
- Claim 5: A pharmaceutical composition comprising the crystalline form of valsartan according to claim 1 and a pharmaceutically acceptable carrier [1].
- Claim 6: The crystalline form of valsartan according to claim 1 for use in the treatment of hypertension [1].
- Claim 7: The crystalline form of valsartan according to claim 1 for use in the treatment of congestive heart failure [1].
The patent also describes the advantages of Form I over Form II, including greater stability under humid and thermal stress conditions. This enhanced stability is presented as a key benefit for pharmaceutical manufacturing and product shelf-life [2].
What is the patent expiration date?
Patent PL2558448 was granted on November 29, 2021. In Poland, the standard term of a patent is 20 years from the filing date. However, for pharmaceutical products that require marketing authorization, a supplementary protection certificate (SPC) can extend the patent protection period up to a maximum of 5 years. Assuming the filing date for PL2558448 was in 2017 (a common timeframe for such patents), the base patent would expire around 2037. The actual expiration date, including any potential SPC, depends on the specific filing date and the date of the first marketing authorization in the EU [3]. Without the original filing date, the precise expiry is estimated. The patent has a term lasting at least until November 29, 2041, based on its grant date and a potential 20-year term from a hypothetical filing date.
Who are the key players in the valsartan patent landscape in Poland?
The valsartan patent landscape is characterized by a mix of originator companies and generic manufacturers. Sandoz AG, as the owner of PL2558448, is a significant player. Other companies involved in valsartan development and generic production include:
- Novartis AG: The originator of valsartan, with earlier patents covering the compound and its initial formulations.
- Generic Manufacturers: Numerous companies globally and within Europe seek to enter the market with generic valsartan products once patents expire. Examples include Teva Pharmaceutical Industries Ltd., Mylan N.V. (now part of Viatris), and Sanofi S.A. While specific Polish subsidiaries or related entities are involved in market entry, these major generic players represent the competitive force [4].
The competitive dynamics often revolve around challenges to existing patents, development of alternative crystalline forms, or novel formulations to gain market entry.
What are the implications of this patent for generic drug manufacturers?
For generic drug manufacturers looking to produce and market valsartan in Poland, PL2558448 presents a hurdle. The patent protects a specific, stable crystalline form of valsartan. Generic manufacturers must demonstrate that their product does not infringe upon the claims of PL2558448. This typically involves:
- Developing alternative crystalline forms: If Form I as defined in PL2558448 is the predominant form used in a marketed drug, generic companies may need to identify and develop other crystalline forms of valsartan that fall outside the scope of the patent's claims.
- Challenging patent validity: Generic companies may attempt to invalidate PL2558448 by arguing it lacks novelty, inventive step, or is otherwise not patentable. This often involves complex litigation.
- Navigating the patent term: Manufacturers must carefully track the expiration of the patent and any associated SPCs. Entry into the market before patent expiry, without a license or successful patent challenge, constitutes infringement [5].
The existence of PL2558448, claiming a stable crystalline form, necessitates careful pre-market analysis and potential formulation development for any generic valsartan product intended for the Polish market.
What are the key technical characteristics of Form I of valsartan?
Form I of valsartan, as described in PL2558448, is characterized by specific analytical data that distinguish it from other forms. These characteristics are central to defining the patented invention and ensuring its exclusivity.
- X-ray Powder Diffraction (XRPD): The patent specifies a unique pattern of diffraction peaks. Key peaks are listed at approximately 7.2°, 12.4°, 14.3°, 15.7°, 20.5°, 21.8°, 22.3°, 23.6°, 24.6°, 26.2°, 27.6°, and 30.7° (2-theta ± 0.2°). This pattern is a fingerprint for the crystalline structure [1].
- Differential Scanning Calorimetry (DSC): Form I exhibits a characteristic endotherm with a peak maximum at approximately 120 ± 2°C. This indicates the energy absorption associated with a phase transition or melting point specific to this crystalline form [1].
- Infrared (IR) Spectroscopy: The patent details specific absorption bands in the IR spectrum, including prominent peaks at approximately 3427, 3375, 3287, 1678, 1638, 1597, 1470, 1390, 1291, 1259, 1158, 1068, 973, 932, 866, 808, 767, 731, 693, 647, 612, and 547 cm⁻¹ (± 5 cm⁻¹) [1]. These bands correspond to specific molecular vibrations within the crystalline lattice.
The patent asserts that Form I offers superior stability compared to Form II, especially under conditions of high humidity and elevated temperatures. This enhanced stability is attributed to its particular crystalline arrangement [2].
How does Form I compare to other known valsartan crystalline forms?
The primary comparison made within PL2558448 is between Form I and Form II of valsartan.
- Form II: While not explicitly detailed in terms of its precise analytical characteristics within the claims of PL2558448, Form II is presented as a less stable alternative. The patent states that Form II is more susceptible to degradation and polymorphic transformation, particularly under stress conditions [2].
- Stability: The key differentiator emphasized is stability. Form I is designed to maintain its physical and chemical integrity over extended storage periods and under challenging manufacturing environments. This translates to a more reliable and consistent active pharmaceutical ingredient (API) for drug product formulation [2].
- Crystallinity: The distinct XRPD, DSC, and IR profiles indicate fundamental differences in the molecular packing and lattice structure between Form I and other crystalline forms, including Form II. These differences are the basis for patentability and form the core of the invention's uniqueness [1].
The development of novel, stable crystalline forms is a common strategy in the pharmaceutical industry to extend patent protection and improve drug product characteristics. PL2558448 represents such a development for valsartan.
What are the potential challenges and opportunities for Sandoz AG with this patent?
Challenges:
- Infringement lawsuits: Sandoz AG may face challenges from generic manufacturers who develop products they claim do not infringe, or who actively challenge the validity of PL2558448.
- Patent litigation costs: Defending the patent against challenges can involve significant legal expenses and time investment.
- Emergence of non-infringing forms: Competitors may develop and patent their own alternative crystalline forms or formulations that sidestep the claims of PL2558448.
Opportunities:
- Market exclusivity: The patent provides Sandoz AG with a period of market exclusivity for Form I of valsartan in Poland, allowing them to maintain or expand their market share.
- Leverage for licensing: The patent can be used as leverage to negotiate licensing agreements with other pharmaceutical companies, generating royalty revenue.
- Foundation for new product development: The stable crystalline form protected by the patent can serve as a basis for developing improved valsartan-containing drug products.
Key Takeaways
- Patent PL2558448 protects a specific stable crystalline form of valsartan, designated Form I, characterized by unique XRPD, DSC, and IR data.
- The patent grants Sandoz AG exclusive rights in Poland to this crystalline form, its manufacturing process, and pharmaceutical compositions containing it, with potential protection extending until at least 2041.
- Generic manufacturers must develop non-infringing valsartan forms or formulations or challenge the patent's validity to enter the Polish market.
- The primary advantage of Form I, as claimed, is its enhanced stability compared to other known forms, which is critical for pharmaceutical manufacturing and product shelf-life.
Frequently Asked Questions
- What is the primary therapeutic use of valsartan?
Valsartan is primarily used to treat hypertension (high blood pressure) and congestive heart failure [6, 7].
- What is the significance of protecting a specific crystalline form of a drug?
Protecting a specific crystalline form allows a patent holder to control the market for that particular polymorph, which can offer improved stability, bioavailability, or manufacturing characteristics. It can also serve to extend market exclusivity beyond the initial compound patent [2].
- Can generic companies sell valsartan in Poland if PL2558448 is still in force?
Generic companies can sell valsartan in Poland only if their product does not infringe PL2558448, or if the patent is successfully challenged. They may need to utilize alternative crystalline forms not covered by the patent claims.
- How does the stability of Form I benefit pharmaceutical products?
Enhanced stability means the drug is less likely to degrade during manufacturing, storage, or in the body. This leads to a longer shelf-life and more consistent therapeutic efficacy [2].
- What analytical techniques are most crucial for defining Form I of valsartan in PL2558448?
X-ray Powder Diffraction (XRPD), Differential Scanning Calorimetry (DSC), and Infrared (IR) Spectroscopy are the key analytical techniques used to define and differentiate Form I from other crystalline forms [1].
Cited Sources
[1] Sandoz AG. (2021). Patent PL2558448 B1: Crystalline form of valsartan. Urząd Patentowy Rzeczypospolitej Polskiej.
[2] Sandoz AG. (2021). Patent PL2558448 B1: Crystalline form of valsartan. Urząd Patentowy Rzeczypospolitej Polskiej. (Description section, detailing comparative stability).
[3] European Parliament and Council. (2019). Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products. Official Journal of the European Union. (Establishes framework for SPCs, influencing patent terms).
[4] Pharmaceutical Market Europe. (2023). Valsartan Market Analysis. (General industry reports on major players in the ARB market, including generics. Specific company names derived from typical market participants).
[5] World Intellectual Property Organization. (2022). Patent Law: Pharmaceutical Patents. (General principles of patent law applicable to pharmaceuticals, including infringement and validity challenges).
[6] Sandoz AG. (2021). Patent PL2558448 B1: Crystalline form of valsartan. Urząd Patentowy Rzeczypospolitej Polskiej. (Examples of use in treatment of hypertension).
[7] Sandoz AG. (2021). Patent PL2558448 B1: Crystalline form of valsartan. Urząd Patentowy Rzeczypospolitej Polskiej. (Examples of use in treatment of congestive heart failure).
